Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss results and provide a corporate update. Investors can access the webcast through Clearside's website under the Investors section, or join the call using domestic (877) 545-0523 or international (973) 528-0016 dial-in numbers with conference code 756568.
Clearside Biomedical (Nasdaq: CLSD), una compagnia biofarmaceutica focalizzata sulla somministrazione di terapie per il fondo dell'occhio attraverso lo spazio suprachoroidale (SCS®), rilascerà i suoi risultati finanziari del terzo trimestre 2024 martedì 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà un webcast e una conferenza telefonica alle 16:30 ora orientale per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori possono accedere al webcast tramite il sito web di Clearside nella sezione Investitori, oppure partecipare alla chiamata utilizzando i numeri nazionali (877) 545-0523 o internazionali (973) 528-0016 con il codice conferenza 756568.
Clearside Biomedical (Nasdaq: CLSD), una empresa biofarmacéutica centrada en ofrecer terapias a la parte posterior del ojo a través del espacio suprachoroideo (SCS®), publicará sus resultados financieros del tercer trimestre de 2024 el martes 12 de noviembre de 2024, después del cierre del mercado. La compañía llevará a cabo un webcast y una llamada de conferencia a las 4:30 p.m. hora del Este para discutir los resultados y proporcionar una actualización corporativa. Los inversores pueden acceder al webcast a través del sitio web de Clearside en la sección de Inversores, o unirse a la llamada utilizando los números nacionales (877) 545-0523 o internacionales (973) 528-0016 con el código de conferencia 756568.
Clearside Biomedical (Nasdaq: CLSD)는 초코리달 공간(SCS®)을 통해 눈 뒤쪽에 치료를 전달하는 데 주력하는 생명공학 회사로, 2024년 3분기 재무 결과를 2024년 11월 12일 화요일, 시장 폐장 후 발표합니다. 회사는 동부 표준시(EST) 기준으로 오후 4:30에 결과를 논의하고 기업 업데이트를 제공하기 위해 웹캐스트 및 컨퍼런스 콜을 개최합니다. 투자자들은 Clearside의 웹사이트 투자자 섹션을 통해 웹캐스트에 접속하거나, 국내 (877) 545-0523 또는 국제 (973) 528-0016의 전화 회의 코드를 756568로 사용하여 통화에 참여할 수 있습니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise biopharmaceutique axée sur la délivrance de thérapies à l'arrière de l'œil par l'intermédiaire de l'espace suprachoroïdien (SCS®), publiera ses résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024, après la clôture du marché. L'entreprise organisera un webinaire et une conférence téléphonique à 16h30, heure de l'Est, pour discuter des résultats et fournir une mise à jour sur l'entreprise. Les investisseurs peuvent accéder au webinaire via le site Web de Clearside dans la section Investisseurs, ou rejoindre l'appel en utilisant les numéros nationaux (877) 545-0523 ou internationaux (973) 528-0016 avec le code de conférence 756568.
Clearside Biomedical (Nasdaq: CLSD), ein biopharmazeutisches Unternehmen, das sich auf die Bereitstellung von Therapien für den hinteren Teil des Auges durch den suprachoroidalen Raum (SCS®) konzentriert, wird seine Finanzergebnisse für das dritte Quartal 2024 am Dienstag, den 12. November 2024, nach Handelsschluss veröffentlichen. Das Unternehmen wird um 16:30 Uhr Eastern Time ein Webinar und eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über die Website von Clearside im Bereich Investoren auf das Webinar zugreifen oder an der Konferenz anrufen, indem sie die nationalen Nummern (877) 545-0523 oder die internationalen Nummern (973) 528-0016 mit dem Konferenzcode 756568 verwenden.
- None.
- None.
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (877) 545-0523 (domestic) or (973) 528-0016 (international) and entering conference code: 756568. The Company suggests participants join 15 minutes in advance of the event.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), recently completed a Phase 2b clinical trial, and planning for a Phase 3 program is underway. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When will Clearside Biomedical (CLSD) report Q3 2024 earnings?
How can I join Clearside Biomedical's (CLSD) Q3 2024 earnings call?
